Effect of Structural Modification of Enol−Carboxamide-Type Nonsteroidal Antiinflammatory Drugs on COX-2/COX-1 Selectivity
摘要:
Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3-carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4-dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.
DOI:
10.1021/jm9607010
作为产物:
描述:
2,5-二氯噻吩-3-磺酰氯 、 甲胺 在
盐酸 、 Sodium sulfate-III 、 四氯化碳 作用下,
以
氯仿 为溶剂,
反应 2.0h,
以2,5-dichlorothiophene-3-sulfonic acid methylamide having a melting point of 59°-61° is obtained的产率得到2,5-Dichlorothiophene-3-sulfonic acid methyl-amide
The present invention provides a compound that has an excellent inhibitory activity on STAT6 activation and is effective against allergic diseases, and a medicinal composition thereof. According to the present invention, disclosed is the compound represented by the General Formula (I)
[where R
1
and R
2
independently represent a C
1-6
alkyl group and the like that may have a hydrogen atom or a substituent;
R
3
represents a C
1-6
alkyl group and the like that may have a substituent;
R
4
and R
5
independent represents a hydrogen atom or a C
1-6
alkyl group and the like that may have a substituent;
R
6
represents a hydrogen atom and the like;
W represents —SO
2
— and the like; and X represents a sulphur atom and the like.]or a salt thereof, or a hydrate thereof.
Anti-inflammatory, analgesic, anti-rheumatic and anti-thrombotic thienothiazine derivatives having the formula ##STR1## wherein A together with the two carbon atoms forms the group ##STR2## and the dotted line indicates the double bond present in the first and last thieno structures above, R.sup.1 is lower alkyl, R.sup.2 is the radical of an aromatic heterocycle with 1 to 4 hetero atoms optionally substituted by one or two lower alkyl groups, or a phenyl radical optionally substituted by halogen, hydroxy, lower alkyl, trifluoromethyl or lower alkoxy, R.sup.3 is halogen and R.sup.3' is hydrogen or halogen, and pharmaceutically acceptable salts thereof are described.
Thienothiazinderivate, deren Herstellung, sowie diese enthaltende Präparate
申请人:F. HOFFMANN-LA ROCHE & CO.
Aktiengesellschaft
公开号:EP0001113A1
公开(公告)日:1979-03-21
Es werden antiinflammatorisch, analgetisch, antirheumatisch und antithrombotisch wirksame Thienothiazinderivate der allgemeinen Formel
worin A mit den beiden Kohlenstoffatomen die Gruppe
bildet und die gestrichelte Linie die im ersten und letzten Fall vorliegende Doppelbindung anzeigt, R' niederes Alkyl bedeutet, R2 den Rest eines gegebenenfalls durch eine oder zwei niedere Alkylgruppen substituierten aromatischen Heterocyclus mit 1 bis 4 Heteroatomen oder einen gegebenenfsalst durch Halogen, Hydroxy, niederes Alkyl, Trifluormethyl oder niederes Alkoxy substituierten Phenylrest bedeutet, R3 Halogen und R3' Wasserstoff oder Halogen bedeutet, sowie Verfahren zu deren Herstellung beschrieben.
描述了抗炎、镇痛、抗风湿和抗血栓的噻吩噻嗪衍生物的通式,其中 A 构成具有两个碳原子的基团,虚线表示在第一种和最后一种情况下存在的双键,R'表示低级烷基,R2 表示任选被一个或两个低级烷基取代并具有 1 至 4 个杂原子的芳香杂环的基团,或任选被卤素、羟基、低级烷基、三氟甲基或低级烷氧基取代的苯基,R3 表示卤素,R3'表示氢或卤素,并描述了其制备工艺。